A Clinical Study With Adalimumab Biosimilar
Phase 1
Completed
- Conditions
- PharmacokineticsSafety Issues
- Interventions
- Biological: Humira® (adalimumab) AC Pen [Reference Product]Biological: Adalimumab Richmond [Test Product]
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Laboratorios Richmond S.A.C.I.F.
- Target Recruit Count
- 150
- Registration Number
- NCT06291948
- Locations
- 🇦🇷
FP Clinical Pharma S.R.L., Buenos Aires, Argentina
A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab
Phase 1
Completed
- Conditions
- PharmacokineticsSafety Issues
- Interventions
- Biological: Bevacizumab
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Laboratorios Richmond S.A.C.I.F.
- Target Recruit Count
- 112
- Registration Number
- NCT03919448
- Locations
- 🇦🇷
FP Clinical Pharma S.R.L., Buenos Aires, Argentina
© Copyright 2025. All Rights Reserved by MedPath